Life expectancy of patients with myeloproliferative neoplasms (MPNs) and particularly that of subjects with polycythemia vera (PV) and essential thrombocythemia (ET) has significantly increased over the last three decades, largely due to the use of cytoreductive treatments. Currently, polycythemia vera and essential thrombocythemia are considered relatively benign diseases in which the main objective of treatment strategy is the prevention of thrombotic events. Widespread use of routine hematologic screening and novel diagnostic tools greatly facilitate disease recognition and treatment.
Landolfi, R., Di Gennaro, L., Pathophysiology of thrombosis in myeloproliferative neoplasms, <<HAEMATOLOGICA>>, 2011; 96 (2): 183-186. [doi:10.3324/haematol.2010.038299] [http://hdl.handle.net/10807/32497]
Pathophysiology of thrombosis in myeloproliferative neoplasms
Landolfi, Raffaele;Di Gennaro, Leonardo
2011
Abstract
Life expectancy of patients with myeloproliferative neoplasms (MPNs) and particularly that of subjects with polycythemia vera (PV) and essential thrombocythemia (ET) has significantly increased over the last three decades, largely due to the use of cytoreductive treatments. Currently, polycythemia vera and essential thrombocythemia are considered relatively benign diseases in which the main objective of treatment strategy is the prevention of thrombotic events. Widespread use of routine hematologic screening and novel diagnostic tools greatly facilitate disease recognition and treatment.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
